Moligo featured in Dagens Industri

We were very happy to be featured in Dagens Industri today which is Sweden's largest newspaper focussing on business and finance. 

Moligo Technologies was featured because the recent announcement of the Nobel Prize in Chemistry for CRISPR is very closely related to our work. CRISPR is an exciting new technology that has already revolutionized biological research with extraordinary implications for human health. It is a technology that allows us to easily edit the DNA of any organism with simple lab tools.

But, as with any technology discovered in the research lab, making it usable and practically available to the people who need it is a challenge. For CRISPR, one of the biggest challenges has been finding the right DNA components to make the technology safe to use at a scale. This is a huge problem because unless the technology can be used safely and at scale, it will never really affect the health of patients suffering each day in the clinic. 

This is where Moligo comes in, we are enabling the future of CRISPR technology by providing single stranded DNA oligos that unlock new possibilities for genome editing. 

In the past, producers of DNA oligos for CRISPR have struggled with purity and scale. Oligos for CRISPR need to be pure with no unexpected mutations that can make treatments unsafe. Oligos also need to be long enough to cover useful (and sometimes very complex) units of the genome, such as an entire gene which could be several thousand bases long. Most DNA oligo are less than 300 bases meaning that their applications are strictly limited. The final issue with traditional oligos is that they cannot be produced in a very large quantity. Current methods cannot produce enough DNA to treat even one patient, never mind a whole population. 

Without addressing these limitations, it won’t be possible to apply CRISPR technology to some of today’s more pressing health and sustainability issues. 

So at Moligo, we have developed a method that will allow us to produce kilograms of highly pure DNA with lengths up to 10 000 bases. This gives clinical researchers the tools they need to be able to seriously consider CRISPR as a therapeutic method as opposed to a tool that can only be used in the lab.

This is why Dagens Industri was interested in Moligo. With the announcement of the Nobel Prize, suddenly the gaze of the world was on CRISPR and genome editing. Many people at this stage look back over the discovery and celebrate the achievement, which is important. However, we have our eyes set firmly on the future. We see the roadblocks ahead for this technology and we are set on removing them so that everyone can have access to this revolution in biology and human health.